New Hepatitis C Drug for Genotypes 1 and 2
Posted: Feb 17 2016

FDA Drug Approvals

New Brand Approvals
Drug NameUses/TreatmentPricing InformationOther Information
Onzetra Xsail®
(sumatriptan) nasal
Acute treatment of migrane with or without aura in adultsPricing information not yet available• Drug Information: sumatriptan nasal powder, administered using the Xsail breath-powered delivery device, intended for the treatment of acute migraines.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
Zembrace SymTouch®
(sumatriptan) injection
Acute treatment of migrane with or without aura in adultsPricing information not yet available• Drug Information: sumatriptan nasal powder, administered using the Xsail breath-powered delivery device, intended for the treatment of acute migraines.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
Zepatier®
(elbasvir/grazoprevir)
Treatment of chronic hepatitis C virus, genotypes 1 or 4 infection in adultsVaries based on length of treatment, approximately $66,000 to $87,500 for treatment course• Drug Information: Fixed-dose combination product indicated with or without ribavirin for the treatment of chronic hepatitis C virus, genotype 1 or 4 infection.
• Formulary Management: Considered non-preferred upon market entry. 
• BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak’s BIC Specialty Pharmacy Network. 
• Clinical Concierge: Subject to Prior Authorization as a Specialty medication. Drug-specific and evidence-based PA criteria developed and applied by MedTrak’s Clinical Care Center to ensure appropriate utilization.
Control Trak: Subject to Max Dollar and Max Dose edits.